ACAD
$24.26
Acadia Pharmaceutica
($1.37)
(5.35%)
ACAD
Earnings Whisper ®
N/A
2nd Quarter June 2019
Consensus:  ($0.46)
Revenue:  $72.82 Mil
Wednesday
Jul 31
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACAD reports earnings?
Beat
Meet
Miss

Where is ACAD's stock price going from here?
Up
Flat
Down
Stock chart of ACAD
Analysts
Summary of analysts' recommendations for ACAD
Score
Grade
Pivots
Resistance
$26.36
$25.93
$25.10

$24.67

Support
$23.84
$23.41
$22.58
Tweet
Growth
Description
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalMylanCelgeneInterCeptZoetisEndo International plcJohnson & JohnsonBristol-Myers Squibb